14 results about "Insulin secretion" patented technology

The main objective of this invention is to provide a novel manufacturing method capable of efficiently and directly converting or inducing somatic cells into insulin-producing cells. As an example, a method for manufacturing insulin-producing cells is provided, which involves directly differentiating and inducing insulin production from somatic cells. This method includes a step of culturing somatic cells in a serum-free differentiation-induction medium; or a step of culturing somatic cells in a differentiation-induction medium containing 5 μg / mL or more of insulin. According to this invention, insulin-producing cells with high insulin secretion capacity can be efficiently and directly manufactured from somatic cells. The insulin-producing cells obtained by this invention are useful in regenerative medicine and the like.

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.

This invention provides a polypeptide or a pharmaceutically acceptable salt thereof that may be useful in the treatment of type 2 diabetes (T2D), diabetes mellitus with obesity, obesity, and hyperlipidemia. [Solution] Provides a long-acting glucagon-like peptide-1 and a human glucose-dependent insulin secretion-stimulating polypeptide (GIP) biagonal agonist polypeptide.

The application provides a construction method of a cell model for screening hypoglycemic drugs, and belongs to the technical field of biotechnology.The method provided by the application comprises the following steps: cell verification, vector construction and plasmid extraction, cell electroporation, drug screening, stable strain amplification and Q-PCR verification.The application successfully constructs a stable fluorescence reporter model (Min6-ins2>EGFP) based on Min6 cells, and verifies the specificity and sensitivity of the model to insulin secretion promoting drugs through positive drug verification.The model is simple to operate, can be monitored in real time, is suitable for high-throughput screening, can be effectively used for hypoglycemic activity evaluation of complex components such as chemical drugs and traditional Chinese medicines, and provides a reliable tool for early screening of hypoglycemic drugs.

The application discloses a pre-meal nerve electric stimulation control method, device and system. The method comprises the following steps: detecting whether a pre-meal intervention condition is met; when the pre-meal intervention condition is met, generating a biphasic pulse electric stimulation by calling preset output parameters, wherein the preset output parameters comprise a constant stimulation frequency, a constant stimulation pulse width and a stimulation current; and controlling an electrode sheet to output the biphasic pulse electric stimulation to a target vagus nerve site. By outputting the biphasic pulse electric stimulation to the target vagus nerve site when the pre-meal intervention condition is met, the target vagus nerve can be quickly activated before a meal, the body is prepared for adjusting insulin secretion in advance, the postprandial blood glucose peak value can be more effectively flattened, the intervention effect is improved, and thus standard weight management is realized.

The present invention relates to a pharmaceutical composition and a health functional food composition for regulating and improving blood glucose, each comprising, as an active ingredient, a fermented culture supernatant of a Bacillus velezensis KMU01 strain, a concentrate thereof, a dried product thereof, a fermentation metabolite thereof, or a mixture thereof, and having the effects of regulating insulin secretion in serum and lowering fasting blood glucose.

Aspects of the present disclosure include methods for treating a subject having a metabolic disorder by neuromodulation. Methods according to certain embodiments include applying electrical stimulation to the spinal cord of a subject (e.g., a subject diagnosed as having or determined to have diabetes or prediabetes) in a manner sufficient to treat at least one symptom of the metabolic disorder in the subject. In some embodiments, neuromodulation is sufficient to treat one or more symptoms of diabetes or prediabetes such as fasting plasma glucose concentration, non-fasting plasma glucose concentration, elevated hbA1c, glucose tolerance and insulin secretion by the subject. Systems having one or more electrodes configured for applying electrical stimulation to the spinal cord of the subject suitable for practicing the subject methods are also described.

The present application relates to the field of microorganisms, and provides a propionibacterium acidifaciens BL8 with functions of reducing blood sugar and resisting aging, and application thereof, the propionibacterium acidifaciens BL8 is preserved in China General Microbiological Culture Collection Center on December 20, 2024, and the preservation number is CGMCC No.33134.The propionibacterium acidifaciens BL8 of the present application can inhibit DPP4 activity, promote INS-1 insulin secretion, inhibit acetylcholinesterase activity and superior cellulase activity.Can reduce blood sugar;Improve memory, prevent and relieve Alzheimer's disease;Promote cellulose absorption, improve constipation, and have high research and application value in reducing blood sugar and resisting aging.

In this specification, compounds of formula I and their pharmaceutically acceptable salts (wherein R 1 , R 2 , R 3 , L 1 , T 1 , T 2 , T 3 , T 4 , t1, and t2 are as defined herein), their use as GIPR antagonists, pharmaceutical compositions containing such compounds and salts, and the use of such compounds and salts for treating or preventing, for example, obesity, weight gain, and / or T2DM are described. 【Chemical Formula 1】 TIFF2026516633000207.tif175168

The present application relates to the field of biotechnology, in particular to a preparation method of sound-sensitive stem cell-derived beta functional cells and application thereof. The preparation method provided by the present application introduces a prokaryote-derived engineered mechanosensitive ion channel MscL-G22S into human pluripotent stem cells, and combines with a directional differentiation technology to obtain pancreatic islet beta-like cells with ultrasonic response function. The cell product not only has a natural glucose-dependent insulin secretion capacity, but also has an additional function of being activated by low-intensity focused ultrasound in a non-invasive manner through the introduction of an exogenous ion channel. This double regulation mechanism significantly improves the functional maturity and response sensitivity of the transplanted cells in vivo, and can achieve a better blood glucose control effect under the same number of cells, thereby providing a technical possibility for reducing the amount of transplanted cells, reducing the volume of transplanted cells and expanding the transplanted site, and being suitable for popularization and application.

The present invention relates to a peptide having anti-obesity and anti-diabetes activities and uses thereof. The peptide of the present invention increases the expression of insulin genes and genes of PDX1 and GLP1R involved in insulin secretion, increases the secretion of insulin itself, and increases the expression levels of phospho-CREB and POMC factors associated with satiety signaling. In addition, the peptide of the present invention exhibits anti-obesity activity. Therefore, the peptide of the present invention can be used for treating, preventing, and alleviating obesity or diabetes, and can be advantageously used for lowering blood glucose levels of a person in need of blood glucose control.

The application discloses an injectable hydrogel of islet-like spheroids based on double sequential encapsulation and a preparation and application thereof, and belongs to the technical field of bioengineering medical materials. The preparation method utilizes the positive and negative charges of a polymer material, forms an immune protection film of islet beta cells through electrostatic adsorption layer-by-layer self-assembly, and utilizes the extracellular matrix of a spleen, i.e., the characteristics of a liquid state in vitro and self-assembly into a nanofiber gel structure at a physiological temperature in vivo, to prepare the injectable hydrogel of islet-like spheroids, so as to ensure the stability of the hydrogel structure, self-assembly into a nanofiber three-dimensional gel structure in vivo, provide a natural specific microenvironment for cell self-renewal and differentiation, promote the aggregation of beta cells into islet-like spheroids, and enhance the insulin secretion and vascularization capacity. The immune protection film is formed on the surface of the islet beta cells through layer-by-layer self-assembly of gelatin and alginate, so that the beta cell immune protection encapsulation is realized.

The application discloses application of a piRNA-145836 preparation in preparation of a medicine for preventing and treating type 2 diabetes induced by high homocysteine, and belongs to the technical field of biological medicine and molecular biology. The nucleotide sequence of the piRNA-145836 is shown as SEQ ID No. 1. The piRNA-145836 can play a key role in type 2 diabetes induced by high homocysteine, and can regulate a mechanism, promote recovery of pancreatic function, restore insulin secretion capacity, reduce abnormal activation of copper death-related proteins, reduce accumulation of copper ions in islet beta cells, and improve sugar metabolism disorder induced by high homocysteine. The application solves the technical problems of lack of cognition of the role of piRNA in copper ion homeostasis and beta cell fate determination, ambiguity of the role target of resveratrol, and unknown expression regulation mechanism of key copper transport proteins in a high homocysteine environment in the prior art.